179 related articles for article (PubMed ID: 8773449)
1. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice.
Reche I; Fuentes JA; Ruiz-Gayo M
Eur J Pharmacol; 1996 Apr; 301(1-3):75-81. PubMed ID: 8773449
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors.
Reche I; Fuentes JA; Ruiz-Gayo M
Eur J Pharmacol; 1996 Dec; 318(1):11-6. PubMed ID: 9007506
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol.
Berrendero F; Maldonado R
Psychopharmacology (Berl); 2002 Aug; 163(1):111-7. PubMed ID: 12185408
[TBL] [Abstract][Full Text] [Related]
5. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
Manzanares J; Corchero J; Fuentes JA
Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
[TBL] [Abstract][Full Text] [Related]
6. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
[TBL] [Abstract][Full Text] [Related]
7. Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors.
Takahashi RN; Ramos GA; Assini FL
Pharmacol Biochem Behav; 2003 Jul; 75(4):763-8. PubMed ID: 12957217
[TBL] [Abstract][Full Text] [Related]
8. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
10. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
Williams CM; Kirkham TC
Pharmacol Biochem Behav; 2002; 71(1-2):333-40. PubMed ID: 11812541
[TBL] [Abstract][Full Text] [Related]
11. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
Massi P; Fuzio D; Viganò D; Sacerdote P; Parolaro D
Eur J Pharmacol; 2000 Jan; 387(3):343-7. PubMed ID: 10650181
[TBL] [Abstract][Full Text] [Related]
12. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
13. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.
Richardson JD; Aanonsen L; Hargreaves KM
Eur J Pharmacol; 1997 Jan; 319(2-3):R3-4. PubMed ID: 9042616
[TBL] [Abstract][Full Text] [Related]
14. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
15. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
16. Dynorphin-independent spinal cannabinoid antinociception.
Gardell LR; Ossipov MH; Vanderah TW; Lai J; Porreca F
Pain; 2002 Dec; 100(3):243-248. PubMed ID: 12467995
[TBL] [Abstract][Full Text] [Related]
17. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat.
Cox ML; Welch SP
Eur J Pharmacol; 2004 Jun; 493(1-3):65-74. PubMed ID: 15189765
[TBL] [Abstract][Full Text] [Related]
18. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors.
French ED
Neurosci Lett; 1997 May; 226(3):159-62. PubMed ID: 9175591
[TBL] [Abstract][Full Text] [Related]
19. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
20. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
